Your browser is no longer supported. Please, upgrade your browser.
Settings
GLTO [NASD]
Galecto, Inc.
Index- P/E- EPS (ttm)-1.40 Insider Own10.10% Shs Outstand25.26M Perf Week-5.73%
Market Cap139.36M Forward P/E- EPS next Y-2.10 Insider Trans0.00% Shs Float25.20M Perf Month-26.00%
Income-34.80M PEG- EPS next Q-0.46 Inst Own52.50% Short Float0.19% Perf Quarter-53.75%
Sales- P/S- EPS this Y19.40% Inst Trans- Short Ratio1.38 Perf Half Y-
Book/sh6.55 P/B0.90 EPS next Y56.30% ROA- Target Price- Perf Year-
Cash/sh6.95 P/C0.85 EPS next 5Y47.60% ROE- 52W Range5.77 - 17.99 Perf YTD-52.68%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-67.09% Beta-
Dividend %- Quick Ratio30.40 Sales past 5Y- Gross Margin- 52W Low2.60% ATR0.47
Employees28 Current Ratio30.40 Sales Q/Q- Oper. Margin- RSI (14)28.24 Volatility7.45% 6.73%
OptionableNo Debt/Eq0.00 EPS Q/Q30.60% Profit Margin- Rel Volume4.88 Prev Close6.12
ShortableYes LT Debt/Eq0.00 EarningsMar 29 BMO Payout- Avg Volume34.73K Price5.92
Recom1.20 SMA20-7.05% SMA50-35.20% SMA200-50.62% Volume169,365 Change-3.27%
Nov-23-20Initiated SVB Leerink Outperform $27
Nov-23-20Initiated Credit Suisse Outperform $29
Nov-23-20Initiated BofA Securities Buy $21
Apr-15-21 08:00AM  
Mar-29-21 08:30AM  
Mar-23-21 10:26AM  
08:30AM  
Mar-15-21 07:30AM  
Feb-09-21 08:00AM  
Jan-29-21 01:33AM  
Jan-08-21 08:00AM  
Jan-04-21 04:01PM  
Dec-11-20 08:06AM  
Nov-30-20 08:00AM  
Nov-23-20 04:01PM  
Oct-29-20 01:28PM  
Oct-28-20 09:10PM  
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung. Its products also comprise GB2064, which is in Phase I/IIa for the treatment of myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase I/IIa for the treatment of cancer and fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.